ANX005
Phase 2Completed 0 watching 0 views this week⚡ Active
47
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Warm Autoimmune Hemolytic Anemia (wAIHA)
Conditions
Warm Autoimmune Hemolytic Anemia (wAIHA)
Trial Timeline
Nov 10, 2021 → Jan 17, 2023
NCT ID
NCT04691570About ANX005
ANX005 is a phase 2 stage product being developed by Annexon for Warm Autoimmune Hemolytic Anemia (wAIHA). The current trial status is completed. This product is registered under clinical trial identifier NCT04691570. Target conditions include Warm Autoimmune Hemolytic Anemia (wAIHA).
Hype Score Breakdown
Clinical
17
Activity
12
Company
5
Novelty
5
Community
5
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04691570 | Phase 2 | Completed |
| NCT04569435 | Phase 2 | Completed |
| NCT04514367 | Phase 2 | Completed |
Competing Products
12 competing products in Warm Autoimmune Hemolytic Anemia (wAIHA)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Ianalumab + Placebo | Novartis | Phase 3 | 77 |
| rituximab (Mabthera®) + Placebo | Roche | Phase 3 | 77 |
| rilzabrutinib | Sanofi | Phase 2 | 51 |
| Isatuximab SAR650984 | Sanofi | Phase 2 | 51 |
| parsaclisinib + placebo | Incyte | Phase 3 | 74 |
| RVT-1401 680 mg/weekly + RVT-1401 340 mg/weekly | Immunovant | Phase 2 | 49 |
| HMPL-523(300mg PO QD) + Placebo | HUTCHMED | Phase 2/3 | 60 |
| APL-2 | Apellis Pharmaceuticals | Phase 2 | 47 |
| Obexelimab + Obexelimab | Zenas BioPharma | Phase 3 | 72 |
| Fostamatinib 150 mg bid | Rigel Pharmaceuticals | Phase 2 | 44 |
| Fostamatinib disodium | Rigel Pharmaceuticals | Phase 3 | 69 |
| Fostamatinib disodium + Placebo | Rigel Pharmaceuticals | Phase 3 | 69 |